Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Riess

Showing results (1331-1340 of 1,489) with videos related to

Pageof 149
Sort By:
NPJ Parkinson'S Disease|July 27, 2021
Alpha-synuclein research: defining strategic moves in the battle against Parkinson's diseaseLuis M A Oliveira, Thomas Gasser, Robert Edwards, et al.
Human Molecular Genetics|June 14, 2012
Miller (Genee-Wiedemann) syndrome represents a clinically and biochemically distinct subgroup of postaxial acrofacial dysostosis associated with partial deficiency of DHODHJoe Rainger, Hemant Bengani, Leigh Campbell, et al.
Virology|March 4, 2022
The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 - Results from a prospective cohort of outpatient COVID-19 casesKerstin Puchinger, Noemi Castelletti, Raquel Rubio-Acero, et al.
Advanced Materials (Deerfield Beach, Fla.)|July 31, 2015
Hybrid Organic-Inorganic Perovskites (HOIPs): Opportunities and ChallengesJoseph Berry, Tonio Buonassisi, David A Egger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 17, 2005
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patientsDaniela Berg, Marc Niwar, Sylvia Maass, et al.
Neurogenetics|May 1, 1997
SCA2 trinucleotide expansion in German SCA patientsO Riess, F A Laccone, S Gispert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 TrialAlison M Schram, Abdul Rafeh Naqash, Eric B Haura, et al.
Journal of Medical Genetics|November 3, 2022
In-depth characterisation of a cohort of individuals with missense and loss-of-function variants disrupting <i>FOXP2</i>Lottie D Morison, Elisabeth Meffert, Miriam Stampfer, et al.
Plos One|November 28, 2018
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLCMichael E Goldberg, Meagan Montesion, Lauren Young, et al.
Molecular Cancer Therapeutics|February 28, 2018
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.
Pageof 149

Showing results (1331-1340 of 1,489) with videos related to

Sort By:
Pageof 149
NPJ Parkinson'S Disease|July 27, 2021
Alpha-synuclein research: defining strategic moves in the battle against Parkinson's diseaseLuis M A Oliveira, Thomas Gasser, Robert Edwards, et al.
Human Molecular Genetics|June 14, 2012
Miller (Genee-Wiedemann) syndrome represents a clinically and biochemically distinct subgroup of postaxial acrofacial dysostosis associated with partial deficiency of DHODHJoe Rainger, Hemant Bengani, Leigh Campbell, et al.
Virology|March 4, 2022
The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 - Results from a prospective cohort of outpatient COVID-19 casesKerstin Puchinger, Noemi Castelletti, Raquel Rubio-Acero, et al.
Advanced Materials (Deerfield Beach, Fla.)|July 31, 2015
Hybrid Organic-Inorganic Perovskites (HOIPs): Opportunities and ChallengesJoseph Berry, Tonio Buonassisi, David A Egger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 17, 2005
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patientsDaniela Berg, Marc Niwar, Sylvia Maass, et al.
Neurogenetics|May 1, 1997
SCA2 trinucleotide expansion in German SCA patientsO Riess, F A Laccone, S Gispert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 TrialAlison M Schram, Abdul Rafeh Naqash, Eric B Haura, et al.
Journal of Medical Genetics|November 3, 2022
In-depth characterisation of a cohort of individuals with missense and loss-of-function variants disrupting <i>FOXP2</i>Lottie D Morison, Elisabeth Meffert, Miriam Stampfer, et al.
Plos One|November 28, 2018
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLCMichael E Goldberg, Meagan Montesion, Lauren Young, et al.
Molecular Cancer Therapeutics|February 28, 2018
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.
Pageof 149